983. Incidence of Genital Warts Among Adolescents and Young Adults Prior to Human Papillomavirus Vaccination.
Session: Poster Abstract Session: Clinical Studies of Bacterial Infection
Saturday, October 22, 2011
Room: Poster Hall B1
Handouts
  • 983_DeepaCamenga.pdf (147.9 kB)
  • Background: Few studies have examined the epidemiology of genital warts (GW) in teenagers and young adults the United States.  The aim of this study was to describe the incidence of GW in this population in order to provide a baseline assessment prior to the introduction of human papillomavirus vaccination.

    Methods: The study population included 11-30 year old members of Northern California Kaiser Permanente.  We identified all cases of genital warts from members continuously enrolled from 7/1/00 to 7/1/05 by combining wart related ICD-9 codes (078.10, 078.11, 078.19) with a specific location qualifier in the electronic medical record. The qualifier describes the anatomical location of the wart (genital, anal, vulvar etc.) and was recorded by the physician at the time of visit.   We calculated GW incidence rates and also characterized the anatomical sites of disease.  Incident GW cases were identified if a case was recorded after a 12 month disease-free interval.

    Results:  We identified 1684 cases of GW among 181,264 continuously enrolled members.   The incidence of GW was highest among 25-29 year old females (5.59 cases/1000 person years) and males (3.78/1000 person years).  The incidence of GW was higher among females than males in all age groups.  Among females (n=96,790), 63.3% of the 1238 incident genital warts cases were coded to a vulvar location and 21.1% were coded to the cervix.  Among males (n=84,474), 91.6% of the 444 incident genital wart cases were coded as genital, but the exact anatomic location was not recorded.  The majority of GW cases were identified by OB/GYN (68.4%) and Dermatology (14.4%).

    Conclusion: Our study found rates of genital warts similar to those of previous studies using a unique methodology to identify location of the wart.  Incidence was highest in both 25-29 year old females and males, unlike previous studies that found a peak incidence for females 20-24 years of age.  This is one of the only studies to describe anatomic location of genital warts; among females; most occurred on the vulva. Incidence of genital warts prior to HPV vaccine introduction provides baseline data that can be used in future evaluations to measure vaccine impact. In addition, data on incidence of genital warts can inform assessments of cost and burden of this prevalent disease.


    Subject Category: C. Clinical studies of bacterial infections and antibacterials including sexually transmitted diseases and mycobacterial infections (surveys, epidemiology, and clinical trials)

    Deepa Camenga, MD1, Eileen Dunne, MD MPH2, Mayur Desai, PhD3, Julianne Gee, MPH2, Lauri Markowitz, MD2, Ajit deSilva, MPP4 and Nicola Klein, MD, PhD4, (1)Robert Wood Johnson Foundation Clinical Scholars, Yale School of Medicine, New Haven, CT, (2)Centers for Disease Control and Prevention, Atlanta, GA, (3)Yale School of Public Health, New Haven, CT, (4)Kaiser Permanente Vaccine Study Center, Oakland, CA

    Disclosures:

    D. Camenga, None

    E. Dunne, None

    M. Desai, None

    J. Gee, None

    L. Markowitz, None

    A. deSilva, None

    N. Klein, Sanofi Pasteur: Grant Investigator, Research grant
    Merck & Co.: Grant Investigator, Research grant
    GSK: Grant Investigator, Research grant
    Novartis: Grant Investigator, Research grant
    MedImmune: Grant Investigator, Research grant
    Pfizer: Grant Investigator, Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.